A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 434
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : RAEB
Long Form : refractory anemia with excess blasts
No. Year Title Co-occurring Abbreviation
2021 Direct Medical Costs Associated With Treatment Nonpersistence in Patients With Higher-Risk Myelodysplastic Syndromes Receiving Hypomethylating Agents: A Large Retrospective Cohort Analysis. GLM, HMAs, HR-MDS, PPPM
2020 LOC101928834, a novel lncRNA in Wnt/beta-catenin signaling pathway, promotes cell proliferation and predicts poor clinical outcome in myelodysplastic syndromes. AML, AUC, lncRNAs, MDS, ROC
2020 Nationwide epidemiological survey of familial myelodysplastic syndromes/acute myeloid leukemia in Japan: a multicenter retrospective study. OS, RA
2020 The impact of transfusion burden and comorbidities on the prognosis of patients with myelodysplastic syndromes. CCI, ECOG, ECOG, IPSS, MDS, SF
2020 Under-use of Hypomethylating Agents in Patients With Higher-risk Myelodysplastic Syndrome in the United States: A Large Population-based Analysis. CI, HMAs, MDS, OR
2019 A retrospective study comparing azacitidine with decitabine in Chinese patients with refractory anemia with excess blast based on two clinical trials in a single center. AZA, DAC
2019 Decitabine for myelodysplastic syndromes: dose comparison in a real world clinical setting. CRR, ORR, OS
2019 Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. HMA, HR, HR-MDS, OS, PS, SEER, USA
2018 An uncommon t(9;11)(p24;q22) with monoallelic loss of ATM and KMT2A genes in a child with myelodysplastic syndrome/acute myeloid leukemia who evolved from Fanconi anemia. AML, BM, BMF, FA, HSCT, MDS
10  2018 Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome. FAB, Hb, MCHC, MDS, OS, RA, RAEB-T, RDW
11  2018 Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia. ALDH2, AML, BMF, FA, HSCT, MDS
12  2017 IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes. CI, HR, IDH, MDS
13  2017 TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. CI, HR, MDS
14  2017 Transcriptome analysis of CD34+ cells from myelodysplastic syndrome patients. AML, MDS, RA, RARS
15  2016 Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. MDS
16  2016 Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms. AML, CMML, MDS, MDS-EB, RCMD-RS
17  2016 Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia. BM, CTRLs, JMML, MDS, RAEB-t, RCC
18  2016 Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. HMAs, MDS, SEER
19  2016 Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. BM, MDS, NECs, TNCs
20  2016 Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes. CD, MDS
21  2016 Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. ---
22  2016 The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50. WHO
23  2015 A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. MDS, RCMD
24  2015 Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. NK
25  2015 Myelodysplastic syndromes in Chernobyl clean-up workers. CMML, MDS, RA, RARS
26  2015 Salvaged single-unit cord blood transplantation for 26 patients with hematologic malignancies not in remission. CBT, DFS, GVHD, HLA, NRM, OS, PES, TNC
27  2015 Survey of expert opinions and related recommendations regarding bridging therapy using hypomethylating agents followed by allogeneic transplantation for high-risk MDS. HMAs, MDS, SCT
28  2014 Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. AHSCT, AML, DFS, GVHD, JMML, MDS, NRM, OS, RAEB-T, RCC
29  2014 Artesunate induces apoptosis through caspase-dependent and -independent mitochondrial pathways in human myelodysplastic syndrome SKM-1 cells. AML, ART, MDS, MMPs, PBM, PI
30  2014 Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan. MDS, RAEB-t
31  2014 Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. AML, HSPCs, MDS, RCMD
32  2014 Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy. MDS
33  2014 Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. AML, MDS, mRNA, SF
34  2014 Usefulness of magnetic resonance imaging as a prognostic variable in myelodysplastic syndromes. LDH, MRI, RA, RT
35  2013 Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. GMPs, HSCs, MDS
36  2013 Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. AML, ESA, MDS, OS
37  2013 Over-expression of cancerous inhibitor of PP2A (CIP2A) in bone marrow cells from patients with a group of high-risk myelodysplastic syndromes. CIP2A, MDS, p-c-MYC, PP2A
38  2013 The myelodysplastic syndromes: a personal recollection of four decades of classification and prognostic scoring systems. CMML, FAB, MDS
39  2012 5-azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. CMML-2, IWG, MDS, RCMD
40  2012 A new recurrent chromosomal translocation t(3;11)(q13;q14) in myelodysplastic syndromes associated with overexpression of the ILDR1 gene. AML, MDS, RA
41  2012 Acute myeloid leukemia (AML) with erythroid predominance exhibits clinical and molecular characteristics that differ from other types of AML. AML, MDS
42  2012 Bullous pemphigoid in an elderly patient with myelodysplastic syndrome and refractory anemia coupled with excess of blast. BP
43  2012 Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. IntermRIC, MC, NMA, RIC
44  2012 Comparison of the distribution and clonal expansion features of the T-cell gammadelta repertoire in myelodysplastic syndrome-RAEB and RAEB with progression to AML. AML, MDS, RAEB-AML, TCR
45  2012 High frequency of human leukocyte antigen class II DRB1*1602 haplotype in Greek patients with myelodysplastic syndrome and of DRB1*1501 in the low-risk subgroup. HLA, MDS, RA, RAEB-t, RARS
46  2012 Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome. MDS, PCR, RCMD
47  2012 Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study. ECM, HSCT, RAEB-T
48  2012 Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. AML, MDS
49  2012 [Clinical significance of the Wilms' tumor 1 mRNA expression in childhood myelodysplastic syndrome]. AA, AML, CAA, MDS, RC, RQ-PCR, SAA, WT1
50  2012 [Cytogenetic peculiarity of chromosomal abnormalities in myelodisplastic syndromes in childhood]. Chr, MDS, RA, RCMD
51  2011 Advances in the prognostication and management of advanced MDS in children. AML, HSCT, MDR-AML, MDS, RAEB-T
52  2011 Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population. CI, MDS, OR, RCMD
53  2011 Clinical observation of the treatment of myelodysplastic syndrome mainly with Qinghuang Powder. FAB, IPSS, MDS, QHP, RA
54  2011 Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature. CMML, MDS, WHO
55  2011 Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. IDH, MDS
56  2011 Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. FA, HPCs, MDS, MSCs
57  2011 Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C. ADL, AML, CGA, CIRS, HDACi, IADL, VPA
58  2011 Outcome of allogeneic stem cell transplantation with a conditioning regimen of busulfan, cyclophosphamide and low-dose etoposide for children with myelodysplastic syndrome. CR, MA, MDS, NRM, RC, SCT
59  2011 Pilot study on combination of azacitidine and low-dose cytarabine for patients with refractory anemia with excess blast. allo-SCT, CR, OS
60  2011 [Expression of CD133 in the bone marrow of patients with myelodysplastic syndrome and its clinical significance]. AA, MDS, RCMD
61  2010 HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. aGVHD, HSCT, LFS, MDS, NRM
62  2010 Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. ATG, BSC, IPSS, MDS, OS, TFS
63  2010 Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. AEs, BSC, CALGB, CCR, FAB, MDS
64  2010 Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. LDara-C, MDS
65  2010 Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. BMT, DFS, MDS, RAEB-t, RC, RR
66  2010 [Systemic and autoimmune manifestations in myelodysplastic syndromes]. CMML, MDS
67  2009 Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure. Bz, MDS, MDS-Eo, MDS-U, OR, RA, RCMD, RCUD
68  2009 Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. aGVHD, AML, ANC, CI, EBV, EFS, GVHD, MDS, MMF, NRM, RA, RAEB-T, TBI, TNC
69  2009 [The application of a new prognostic score system for 435 cases of primary myelodysplastic syndrome diagnosed with WHO classification]. IPSS, MDS, NAC, OS, RCMD, WPSS
70  2008 Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. AML, MDSs, SNP-A, TSG
71  2008 Acquired haemoglobin H disease associated with myelodysplastic syndrome. Hb H, LDH, MDS
72  2008 AML1 mutations induced MDS and MDS/AML in a mouse BMT model. AML, BMT, MDS
73  2008 Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal. BM, PMN
74  2008 Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. IPC
75  2008 Cytogenetic abnormalities in Tunisian de novo myelodysplastic syndrome: a comparison with other populations. BM, CMML, FAB, MDS, RA, RAEB-t, RARS
76  2008 Global gene expression profile in myelodysplastic syndromes using SAGE. MDS, SAGE
77  2008 High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia. AML, APL, CVD, HTLV-I, MDS, RA, RAEB-T
78  2008 Human urine extract CDA-2 induces apoptosis of myelodysplastic syndrome-derived MUTZ-1 cells through the PI3K/Akt signaling pathway in a caspase-3-dependent manner. FLIP, IAP, MDS, PI3K
79  2008 Unbalanced whole-arm translocation der(5;19)(p10;q10) is a novel and recurrent cytogenetic aberration in myelodysplastic syndrome. MDS
80  2008 [WHO classification and cytogenetic analysis of 435 cases with myelodysplastic syndrome]. FISH, IPSS, MDS, MDS-U, RA, RAS, RCMD
81  2007 A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. AML, CMML, FLT3-LM, MDS, MLL-PTD, RARS, sAML
82  2007 AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. AKAP12, AML
83  2007 CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. AML, BGS, BM, CR, HI, MDS, OS, RA
84  2007 Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome. CMML, MDS, PNH, RAEB-t, RARS
85  2007 Donor lymphocyte infusions for post-transplant relapse of refractory anemia with excess blasts and monosomy 7. BMT, DLI, GVHD, GVMDS, MC
86  2007 Double minutes (dmin) and homogeneously staining regions (hsr) in myeloid disorders: a new case suggesting that dmin form hsr in vivo. dmin, HSR, MDS, RAEB-T
87  2007 Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. CN, IPSS, LOH, MDS, RA, RARS, RCMD, RCMD-RS, SNP, UPD
88  2007 Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. G-CSF, HLA, HSCT, MDS, TBI
89  2006 A breast cancer patient with myelodysplastic syndrome postoperatively treated by radiation and tamoxifen administration--a case report. MDS
90  2006 An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia. AML, ASCT, PBSC, sAML
91  2006 Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. MDS, RAEB-T, RTK
92  2006 Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. CMML, FAB, RA, RAEB-T, RARS, VEGF
93  2006 Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS. AML, MDS, RAEB-T
94  2006 Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. CMML, MDS, MDS-AML, RA, RAEB-T
95  2006 Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. MDS, RARS, RCMLD
96  2006 Myelodysplastic syndrome with erythroid hypoplasia: a rare and distinct clincopathological entity--a report of two cases. MDS, RA
97  2006 Myelodysplastic syndromes with isolated deletion of the long arm of the chromosome X as a sole cytogenetic change. MDS
98  2006 Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. IWG
99  2006 Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome. AML, MDS, RAEB-T
100  2006 Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. FAB, WHO